These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 35748587)
1. Resistance to BRAF/MEK Inhibition in Melanoma Is Mediated by the Androgen Receptor. Cancer Discov; 2022 Aug; 12(8):1835. PubMed ID: 35748587 [TBL] [Abstract][Full Text] [Related]
2. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS; Sini P; Smalley KS Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592 [TBL] [Abstract][Full Text] [Related]
4. [BRAF inhibitor and MEK inhibitor]. Uhara H Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982 [No Abstract] [Full Text] [Related]
5. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor is a determinant of melanoma targeted drug resistance. Samarkina A; Youssef MK; Ostano P; Ghosh S; Ma M; Tassone B; Proust T; Chiorino G; Levesque MP; Goruppi S; Dotto GP Nat Commun; 2023 Oct; 14(1):6498. PubMed ID: 37838724 [TBL] [Abstract][Full Text] [Related]
7. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154 [TBL] [Abstract][Full Text] [Related]
8. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679 [TBL] [Abstract][Full Text] [Related]
9. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
10. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642 [TBL] [Abstract][Full Text] [Related]
11. A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma. Ruiz EM; Alhassan SA; Errami Y; Abd Elmageed ZY; Fang JS; Wang G; Brooks MA; Abi-Rached JA; Kandil E; Zerfaoui M Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176114 [TBL] [Abstract][Full Text] [Related]
12. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024 [TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
14. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163 [TBL] [Abstract][Full Text] [Related]
15. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
16. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478 [TBL] [Abstract][Full Text] [Related]
17. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672 [TBL] [Abstract][Full Text] [Related]
18. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438 [TBL] [Abstract][Full Text] [Related]